Search
Menu
Home
HTB
2024
August
August 2024
Contents
Conference reports
AIDS 2024: Ten early reports
Five days on two days off: Biktarvy in pilot FOTO study
Subcutaneous formulation of long-acting CAB/RPV discontinued
First data on third-generation integrase inhibitor from ViiV
Switching to daily oral bictegravir and lenacapavir dual therapy to simplify ART in ARTISTRY-1 study
Antiretrovirals
BMS to discontinue atazanavir/cobicistat (Evotaz) in September 2024
mpox (monkeypox)
WHO declares new mpox emergency (clade 1b): tecovirimat not effective in DRC study
HTB RSS
Early access
IAS statement: PEPFAR freeze threatens millions of lives
25 January 2025
Trump bans travel for US government scientists, presentations restricted, documents disappearing
23 January 2025
i-Base guides updated online
5 December 2024
All early access reports
Current issues
January 2025
December 2024
November 2024
Back issues
Special report
Almost 1 in 5 people in Switzerland disconnected from HIV care over 10 years: only half reconnected and with advanced infection
22 January 2025
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage
Donate